Table 4: Propensity Score-Matched Analysis with Average Treatment Effects on imputed data

|  |  |  |  |
| --- | --- | --- | --- |
| Analysis | Group | Odds Ratio (95% CI) | P Value |
| In-hospital mortality  (n=19,766 | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 0.46  (0.13  to  0.80) | 0.002 |
| 30-day mortality  (n=19,766) | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 0.77  (0.34 to 1.22) | 0.312 |
| 1-y mortality  (n=19,766) | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 0.89  (0.62  to  1.18) | 0.454 |
| No reflow/slow flow phenomenon (20,069) | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 2.29 (1.52-3.08) | 0.001 |
| In-hospital MACE  (n=19,766) | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 0.79  (0.37  to  1.22) | 0.336 |
| In-hospital Stroke  (n=19,766) | Group 1: No use of EPD in PCI |  |  |
| Group 2: EPD use in PCI | 0.89  (-1.08  to  2.87) | 0.91 |

n; number of observations, MACE; defined as a composite of in-hospital mortality, in-hospital myocardial reinfarction, and emergency target vessel revascularization)

EPD; Embolic protection devices, CI; Confidence interval, OR; Odds ratio, HR; Hazard ratio, MACE; Major adverse cardiovascular event, PCI; Percutaneous coronary intervention